Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Science-Based Thinking Promises Global Progress On Biosimilars

Samsung Bioepis’ Gillian Woollett Discusses Latest Regulatory Developments

Executive Summary

A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.

You may also be interested in...



Generics Bulletin Editor’s Picks For Q4 2022

Looking back over the fourth quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from October to December that include a leadership change for one of the top industry players, some key developments for biosimilars and the announcement of the winners of our annual awards.

Joined-Up Approach Must Underpin European Biosimilar Procurement

A more joined-up approach is needed on European procurement if the biosimilars market is to remain sustainable in the face of pricing and cost pressures, according to a discussion by industry stakeholders at Medicines for Europe’s 18th Biosimilar Medicines Conference.

Streamlined European Pathway Needed For Biosimilars To Hit Smaller Targets

A more streamlined European regulatory pathway for biosimilars – potentially removing the requirement for confirmatory efficacy trials – is needed for the industry to be able to feasibly offer competition to smaller-value biologic brands, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel